Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies
Tóm tắt
Acetaminophen has several pharmacologic properties that suggest it could be carcinogenic in human beings. A number of epidemiologic studies have been conducted to examine whether use of acetaminophen actually predisposes to the occurrence of one or more forms of cancer. There are inherent limitations to many of these studies, including the inaccurate identification of users and nonusers of acetaminophen, relatively short follow-up for cancer incidence, and the potential for confounding by indication. The present manuscript reviews the results of epidemiologic studies of acetaminophen use in relation to cancer incidence published through the end of 2015. The limitations of the underlying studies notwithstanding, some interim conclusions can be reached. For all but several forms of cancer, there is no suggestion that persons who have taken acetaminophen are at altered risk, even persons who have consumed a large quantity of the drug or those who have taken it for an extended duration. While in some studies the incidence of renal cell carcinoma has been observed to be increased among acetaminophen users, several other studies have failed to observe any such association; the reason for the discrepant findings is unclear. Some of the small number of studies that have presented data on the incidence of lymphoma, leukemia, and plasma cell disorders have found the risk to be modestly higher in users than nonusers of acetaminophen, but the results of other studies of these malignancies will be needed to gauge the possible role of publication bias as the basis for the positive results.
Tài liệu tham khảo
Habel LA, Friedman GD (2006) Pharmaceuticals other than hormones. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Oxford, New York
Bergman G, Muller L, Teigen SW (1996) The genotoxicity and carcinogenicity of paracetamol: a regulatory review. Mutat Res 349:263–288
Bender RP, Lindsey RH, Burden DA, Osheroff N (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 43:3731–3739
Anderson LA, Johnston BT, Watson RG et al (2006) Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 66:4975–4982
Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC (2008) Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17:1169–1178
Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12:88–93
Harris RE, Beebe-Donk J, Alshafie GA (2008) Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8:237
Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303–309
Muscat JE, Stellman SD, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74:1847–1854
Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154:394–399
Walter RB, Brasky TM, White E (2011) Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study. Cancer Epidemiol Biomarkers Prev. 20:2637–2641
Friis S, Nielsen GL, Mellemkjaer L et al (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97:96–101
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327
Tan XL, Reid Lombardo KM, Bamlet WR et al (2011) Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila) 4:1835–1841
Olsen JH, Friis S, Poulsen AH et al (2008) Use of NSAIDs, smoking and lung cancer risk. Br J Cancer 98:232–237
Harris RE, Beebe-Donk J, Alshafie GA (2007) Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci. 3:328–334
Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66–70
Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L (2011) Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 22:1553–1561
Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169:115–121
Friis S, Thomassen L, Sorensen HT et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17:88–96
Garcia-Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525–529
Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101
Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27
Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812
Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159
Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440
Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 30:3468–3477
Setiawan VW, Matsuno RK, Lurie G et al (2012) Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 21:1441–1449
Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68:2507–2513
Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009) Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 170:1512–1517
Moysich KB, Baker JA, Rodabaugh KJ, Villella JA (2005) Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:2923–2928
Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer 132:1146–1155
Trabert B, Ness RB, Lo-Ciganic WH et al (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106:1–11
Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108:281–286
Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169:1378–1387
Rodriguez C, Henley SJ, Calle EE, Thun MJ (1998) Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet 352:1354–1355
Baandrup L, Friis S, Dehlendorff C, Andersen KK, Olsen JH, Kjaer SK (2014) Prescription use of paracetamol and risk for ovarian cancer in Denmark. J Natl Cancer Inst. doi:10.1093/jnci/dju111
Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB (2012) Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 23:311–319
Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H (2001) Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 10:903–906
Rosenberg L, Palmer JR, Rao RS et al (2000) A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 9:933–937
Jacobs EJ, Newton CC, Stevens VL, Gapstur SM (2011) A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 20:1322–1328
Garcia-Rodriguez LA, Gonzalez-Perez A (2004) Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:649–653
Salinas CA, Kwon EM, FitzGerald LM et al (2010) Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172:578–590
Murad AS, Down L, Davey SG et al (2011) Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 128:1442–1448
Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7:169–170
Platz EA, Rohrmann S, Pearson JD et al (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14:390–396
Veitonmaki T, Murtola TJ, Maattanen L et al (2014) Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer 111:1421–1431
Derby LE, Jick H (1996) Acetaminophen and renal and bladder cancer. Epidemiology 7:358–362
Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC (1999) Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81:542–548
Kaye JA, Myers MW, Jick H (2001) Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 12:690–694
Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA (1993) Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 4:101–110
McCredie M, Pommer W, McLaughlin JK et al (1995) International renal-cell cancer study. II. Analgesics. Int J Cancer 60:345–349
Rosenberg L, Rao RS, Palmer JR et al (1998) Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 9:83–88
Cho E, Curhan G, Hankinson SE et al (2011) Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 171:1487–1493
Zhang H, Jiang D, Li X (2013) Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies. PLoS ONE 8:e70008
Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D (2012) Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study. Cancer Causes Control 23:1451–1461
Gamba CA, Swetter SM, Stefanick ML et al (2013) Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Cancer 119:1562–1569
Torti DC, Christensen BC, Storm CA et al (2011) Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 65:304–312
Wysong A, Ally MS, Gamba CS et al (2014) Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the Women’s Health Initiative. Prev Med 69C:8–12
Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M (2004) Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol 159:1131–1139
Kato I, Koenig KL, Shore RE et al (2002) Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin’s lymphoma (NHL) (United States). Cancer Causes Control 13:965–974
Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301–308
Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case-control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375–389
Walter RB, Milano F, Brasky TM, White E (2011) Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 29:2424–2431
Becker N, Fortuny J, Alvaro T et al (2009) Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol 135:1099–1107
Chang ET, Zheng T, Weir EG et al (2004) Aspirin and the risk of Hodgkin’s lymphoma in a population-based case-control study. J Natl Cancer Inst 96:305–315
Moysich KB, Bonner MR, Beehler GP et al (2007) Regular analgesic use and risk of multiple myeloma. Leuk Res 31:547–551
Weiss JR, Baker JA, Baer MR, Menezes RJ, Nowell S, Moysich KB (2006) Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res 30:164–169